Avadel Pharma says its sleep disorder drug remains under FDA review

Avadel Pharmaceuticals

12/09/2024 12:31

Sept 12 (Reuters) - Avadel Pharmaceuticals'  AVDL.O 
sleep disorder drug for use in pediatric patients seven years
and older remains under review by the U.S. Food and Drug
Administration, the company said in a regulatory filing on
Thursday. 
    The health regulator was expected to make a decision by
Sept. 7. Avadel did not provide details on a new action date. 

 (Reporting by Unnamalai L, Christy Santhosh and Bhanvi Satija
in Bengaluru; Editing by Shailesh Kuber)
 ((Unnamalai.L@thomsonreuters.com;))